Hi Ryn, I am not sure we did anything accidentally, but I know what you are suggesting.
That said, ATL-1102 may have the same efficacy or better at a lower dose, or it might not.
There are also various reasons the efficacy at say week 12 was better than week 8, for example, could be an exposure aspect, or it could be that the effects are cumulative or that they take some time to filter through to be more effective. In other words "time" might or might not have been a factor also.
These are the types of things that would be born out of a ph2b/3 trial if and when it is possible.
Longer duration and more variable doses.
I expect to see that trial
What we do know, again thanks to our friend the MRI
Hi Ryn, I am not sure we did anything accidentally, but I know...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |